Infinity Pharmaceuticals Inc. (INFI)

August 16, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 2

Price Open 2

Volume: 99,896

Avg Volume: 300,332

Market Cap: 113.7M

P/E Ratio -3.45

52 Wk Range 0.9255-3.75



INFI Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
54.07M
1.71M
6.72
3.15%

2018-07-13
53.29M
1.53M
2.00
2.87%

2018-06-29
53.29M
1.61M
1.72
3.02%

2018-06-15
53.29M
1.58M
2.92
2.96%




INFI Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-07
Q2 2018
AMC
-0.20 (4)
-0.12
0.08

2018-05-08
Q1 2018
N/A
-0.18 (3)
-0.18
0.00

2018-03-15
Q4 2017
AMC
-0.25 (2)
-0.18
0.00

2018-03-13
Q4 2017
N/A
-0.25 (3)
-0.18
0.00

News

Verastem: An Undervalued Rare Oncology Gem With Big Upcoming Catalysts (2018-08-14 22:50 SeekingAlpha)

Editor's note: Seeking Alpha is proud to welcome Juha Natunen as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Editor's not…

 


Statistics

Shares Outstanding: 56.85M

Top 15 Institution Percent: 59.00

Price To Sales: 18.86

Price To Book: 2.48

Revenue: 6.00M

Gross Profit: N/A

Cash: 55.58M

Debt: N/A

Return On Assets: -43.37

Return On Equity: -59.00

Profit Margin: N/A

Price History

Beta: 2.12

50-day Moving Avg: 1.90

200-day Moving Avg: 2.05

YTD Change: -10.31

5-day Change: -5.21

1-month Change: -1.96

3-month Change: -3.85

6-month Change: 7.53

1-year Change: 80.18

Revenue Per Share: 0.00

Revenue Per Employee: 272727.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Infinity Pharmaceuticals Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.infi.com

Infinity Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. It is focused on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate.